Navigation Links
American Society for Microbiology honors Walter Stamm

Washington, DCJune 25, 2008 The 2008 American Society for Microbiology (ASM) sanofi-aventis U.S. Award will be presented to Walter Stamm, Associate Director, WWAMI Regional Center of Excellence for Biodefense and Emerging Infectious Diseases, Seattle, Washington. Supported by an unrestricted grant from sanofi-aventis U.S., this award honors outstanding accomplishment in antimicrobial chemotherapy.

Through his professional life, Dr. Stamm has worked with antimicrobial resistance for urinary tract infections, chlamydia infections, and sexually transmitted infections. He is recognized as a leader in the antimicrobial therapy of urinary tract infections and has written guidelines for the therapy of chlamydia and other STIs for the Centers for Disease Control and Prevention. Dr. Stamm has published over 300 peer-reviewed papers, about 100 book chapters, and 11 books, most of them about urinary tract infections and genital infections including the role of bacterial pathogenesis, antimicrobial susceptibility and resistance. From 1999 through 2000, Dr. Stamm was a visiting scientist for the World Health Organization in the Antimicrobial Drug Resistance and Surveillance Branch.

Dr. Stamm received his B.A. in Biological Sciences from Stanford University and his M.D. from Harvard Medical School.. He completed his residency at the University of Washington.

The sanofi-aventis U.S. Award will be presented during ASM's 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th IDSA Annual Meeting, October 25 October 28, 2008 in Washington, DC. ASM is the world's oldest and largest life science organization and has more than 43,000 members worldwide. ASM's mission is to advance the microbiological sciences and promote the use of scientific knowledge for improved health and economic and environmental well-being.


Contact: Garth Hogan
American Society for Microbiology

Page: 1

Related biology news :

1. American Chemical Societys Weekly PressPac -- Aug. 8, 2007
2. Understanding hypertension in African Americans proves elusive
3. Tips from the Journals of the American Society for Microbiology
4. American Chemical Societys Weekly PressPac -- Aug. 15, 2007
5. American College of Medical Genetics responds to new FDA labeling decision for warfarin
6. American Chemical Societys Weekly Press Pac
7. Highlights from the September 2007 Journal of the American Dietetic Association
8. American Chemical Societys Weekly Presspac -- Aug. 29, 2007
9. Report: African, Asian, Latin American farm animals face extinction
10. American Chemical Society calls green chemistry bill a smart step
11. Challenges remain in reintroducing American chestnut
Post Your Comments:
(Date:6/22/2016)... ANGELES , June 22, 2016 /PRNewswire/ ... identity management and verification solutions, has partnered ... edge software solutions for Visitor Management, Self-Service ... provides products that add functional enhancements ... partnership provides corporations and venues with an ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: